Management Articles

Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.

The Long Road to NASH Therapeutics: Uncovering Valuable Insights

Authors: Tilg H, Byrne CD and Targher G
Published in The Lancet Gastroenterology and Hepatology (October 2023)
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Read MoreThe Long Road to NASH Therapeutics: Uncovering Valuable Insights

Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Authors: Pais R, Cariou B, Noureddin M et al.
Published in Journal of Hepatology (September 2023)
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Read MoreManaging Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Authors: Tacke F, Puengel T, Loomba R et al.
Published in Journal of Hepatology (August 2023)
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Read MoreExploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Authors: Fromenty B, Roden M
Published in Journal of Hepatology (February 2023)
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Read MoreExamining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Insights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?

Authors: Chew NWS, Ng CH, Tan DJH et al.
Published in Cell Metabolism (March 2023)
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
Read MoreInsights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?

NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?

Authors: Sanyal AJ, Magnanensi J, Majd Z et al.
Published in Hepatology Communications (September 2023)
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Read MoreNIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?

“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Authors: Francque SM, Noureddin M, Krag A
Published in Clinical Gastroenterology and Hepatology (August 2023)
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Read More“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Understanding Nash: Symptoms, Detection, And Treatment

Authors: Basu M, Noureddin M, Clark JM
Published in Mayo Clinic Proceedings (September 2022)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Read MoreUnderstanding Nash: Symptoms, Detection, And Treatment

PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Authors: Staels B, Butruille L, Francque S
Published in Journal of Hepatology (July 2023)
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways. Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Read MorePPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

Authors: Li YY, Zheng TL, Xiao SY et al.
Published in Liver International (June 2023)
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
Read MoreBallooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

A brief introduction to the most promising pharmacological agents for NASH

Authors: Ratziu V and Tacke F
Published in Journal of Hepatology (July 2023)
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Read MoreA brief introduction to the most promising pharmacological agents for NASH

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES